Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 551

1.

Patient Preferences and Therapeutic Satisfaction with Topical Agents for Rosacea: A Survey-Based Study.

Williamson T, Cheng WY, McCormick N, Vekeman F.

Am Health Drug Benefits. 2018 Apr;11(2):97-106.

2.

Effects of Educational Messaging on Urgent and Emergent Care-Seeking Behaviors Among Publicly Insured Populations.

Cambon J, Cordier T, Munnich EL, Renda A, Kapur B, Hoxhaj S, Williams M.

Am Health Drug Benefits. 2018 Apr;11(2):86-94.

3.

Standardized Review and Approval Process for High-Cost Medication Use Promotes Value-Based Care in a Large Academic Medical System.

Durvasula R, Kelly J, Schleyer A, Anawalt BD, Somani S, Dellit TH.

Am Health Drug Benefits. 2018 Apr;11(2):65-73. Review.

4.

Delayed Treatment Acceleration in Patients with Rheumatoid Arthritis Who Have Inadequate Response to Initial Tumor Necrosis Factor Inhibitors: Data from the Corrona Registry.

Pappas DA, Gerber RA, Litman HJ, Gruben D, Geier J, Hua WD, Chen C, Li Y, Kremer JM, Andrews JS, Bourret JA.

Am Health Drug Benefits. 2018 May;11(3):148-158.

5.

Changes in Medical Services and Drug Utilization and Associated Costs After Narcolepsy Diagnosis in the United States.

Villa KF, Reaven NL, Funk SE, McGaughey K, Black J.

Am Health Drug Benefits. 2018 May;11(3):137-145.

6.

Comparing Treatment Modalities for End-Stage Renal Disease: A Meta-Analysis.

Queeley GL, Campbell ES.

Am Health Drug Benefits. 2018 May;11(3):118-127.

7.

Is Adequate Nutrition Cost-Effective?

Nash DB.

Am Health Drug Benefits. 2018 May;11(3):115-116. No abstract available.

8.

New Rivals: Integrating Health Benefits to Provide Comprehensive Patient Care.

Branning G, Vater M.

Am Health Drug Benefits. 2018 Apr;11(2):83-85. No abstract available.

9.

20% by 2020.

Nash DB.

Am Health Drug Benefits. 2018 Apr;11(2):63-64. No abstract available.

PMID:
29899813
Free PMC Article
10.

Healthcare Trends for 2018.

Vogenberg FR, Santilli J.

Am Health Drug Benefits. 2018 Feb;11(1):48-54. No abstract available.

11.

Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States.

Maiese EM, Evans KA, Chu BC, Irwin DE.

Am Health Drug Benefits. 2018 Feb;11(1):39-46.

12.

Newly Diagnosed Hepatitis C in the US Commercially Insured Population Before and After the 2012 Implementation of Expanded Screening Guidelines.

Pyenson BS, Dieguez G, Ferro C, Mavinkurve M, Gonzalez YS.

Am Health Drug Benefits. 2018 Feb;11(1):30-37.

13.

Predictors of Transitioning to Incident Chronic Opioid Therapy Among Working-Age Adults in the United States.

Thornton JD, Dwibedi N, Scott V, Ponte CD, Ziedonis D, Sambamoorthi N, Sambamoorthi U.

Am Health Drug Benefits. 2018 Feb;11(1):12-21.

14.

Still at It.

Nash DB.

Am Health Drug Benefits. 2018 Feb;11(1):9-10. No abstract available.

15.
16.

AMCP Nexus 2017 Highlights.

[No authors listed]

Am Health Drug Benefits. 2017 Dec;10(9):465-467.

17.

The Effects of a Sitagliptin Formulary Restriction Program on Diabetes Medication Use.

Tang Y, Huang X, Liu J, Shankar RR, Ganz ML, Rajpathak S.

Am Health Drug Benefits. 2017 Dec;10(9):456-462.

18.

Prospective Bundled Payments in a Changing Environment: The Experience of a Self-Funded, State-Sponsored Plan.

Lawler FH, Wilson FR, Smith GK, Mitchell LV.

Am Health Drug Benefits. 2017 Dec;10(9):441-447.

19.

"Alexa, Refill My Omeprazole".

Nash DB.

Am Health Drug Benefits. 2017 Dec;10(9):439-440. No abstract available.

20.

The Value of Pre-FDA Approval Healthcare Economic Information Exchange Between Payers and Drug Manufacturers.

Fendt PR, Ung B, Vogenberg FR.

Am Health Drug Benefits. 2017 Nov;10(8):424-426. No abstract available.

Supplemental Content

Loading ...
Support Center